ライフサイエンスコーパス: principal investigator

1 by trained researchers and confirmed by the principal investigator.

2 ore the age of 51, the average age of an NIH principal investigator.

3 nd regimen received had been provided by the principal investigator.

4 n oncologists; 37%, women; and 83%, research principal investigators.

5 cal trial ($110,869) and multimode ($59,916) principal investigators.

6 ry 1985 through March 1996 and by queries of principal investigators.

7 n binge diaries and reviewed weekly with the principal investigators.

8 ic training and professional profiles of the principal investigators.

9 Science Foundation's recent mandate that all Principal Investigators address the broader impacts of t

10 l, basic, or social science faculty who were principal investigators), amount of annual income receiv

11 n day 1 of each treatment cycle (28 days) by principal investigator and coinvestigators at the site.

12 are described, and a survey was sent to the principal investigator and primary clinical coordinator

13 ts from an NCI-sponsored meeting with MBCCOP principal investigators and data from a follow-up survey

14 s was supplemented by direct contact between principal investigators and industry sponsors.

15 ent, the type of academic degree held by the principal investigator, and the awarding institute.

16 easing numbers of new agents, fewer domestic principal investigators, and more companies off-shoring

17 dation (NSF) Biological Sciences Directorate principal investigators (BIO PIs), nearly 90% indicated

18 The principal investigator classified the patients previousl

19 lusively conducted basic science research as principal investigators compared with translational rese

20 nd nine other publications coauthored by the principal investigator contain at least one major untrue

21 from a management position, or naming a new principal investigator for a project.

22 dividual participant data requested from the principal investigator for each eligible trial, adjustin

23 The principal investigator from each eligible study was cont

24 While principal investigators garnered a mean of $410,755 in t

25 A majority of principal investigators had a PhD omnia solus (57%), and

26 While pursuing laboratory research as a principal investigator, I have also been a science admin

27 in the context of the author's experience as principal investigator in a large, randomized trial on c

28 Asian Americans are principal investigators in 18.9% of National Institutes

29 All NIH-funded principal investigators in dermatology were categorized

30 n the context of the authors' experiences as principal investigators in the phase I/II and/or phase I

31 ants between 1964 and 2004 stratified by the principal investigators' major degrees (MD, PhD, or MD a

32 MATERIALS AND Original principal investigators obtained ethics approval for eac

33 ACUTE II, and INTERACT were provided by the principal investigator of each study.

34 The principal investigators of all studies that published da

35 e of death) by direct collaboration with the principal investigators of eligible trials.

36 Principal investigators of the trials and their funding

37 participated in our study reported becoming principal investigators on industry clinical trials prim

38 ourth of the members of FASEB Societies were principal investigators on NIH research grants.

39 emic, private-sector physicians who serve as principal investigators on US clinical trials sponsored

40 Randomisation was done by principal investigators or designee at respective centre

41 y while 45% (n = 40) required them only from principal investigators or those conducting research.

42 ical researchers (OR, 1.6; 95% CI, 1.1-2.3), principal investigators (OR, 4.3; 95% CI, 2.8-7.0), facu

43 llocation, but allocation was concealed from principal investigators, participants and their guardian

44 b of a research-intensive faculty member and principal investigator (PI) as both unattainable and und

45 ical Pharmacology/Micromedex), or study site principal investigator (PI) opinion-among patients recei

46 en no quantitative analysis of who becomes a principal investigator (PI).

47 ber of grant-eligible basic-science faculty [principal investigators (PIs)] younger than 46.

48 Chairpersons believed that the principal investigators' previous success with residents

49 Blood Institute-supported publications each principal investigator published in the 5 years before g

50 first draft was written in April 1996 by the principal investigator (S.G.P.) after the consensus grou

51 the role of these authors rather than of the principal investigator(s) as in the previous policy.

52 The funder, principal investigators, site investigators, patients, i

53 Disagreements were reviewed with the principal investigator to reach consensus.

54 located to placebo; none were judged by site principal investigators to be related to study medicatio

55 for extensive response and redrafting by the principal investigator until all members were satisfied.

56 Both the patient and the principal investigator were blinded to the nature of sur

57 All eligible patients were contacted by the principal investigator who was not their physician.

58 total dollar amount of R01 grants awarded to principal investigators with only an MD degree trended d